Real-World data reveals how palbociclib works in everyday breast cancer care
NCT ID NCT04498481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of women with advanced or metastatic HR+/HER2- breast cancer who received Palbociclib combined with hormone therapy in community clinics. The goal was to see how doctors actually prescribe these drugs, how long patients stay on treatment, and what outcomes like survival and side effects occur. It was an observational study, not a test of a new drug, so no direct treatment was given.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer United States
New York, New York, 10017, United States